Protara (TARA) CFO Fabbio has 3,063 RSU shares withheld for taxes
Rhea-AI Filing Summary
Protara Therapeutics Chief Financial Officer reports tax-related share withholding. On January 20, 2026, CFO Patrick Fabbio had 3,063 shares of common stock withheld by Protara Therapeutics to cover income tax obligations tied to the vesting of a restricted stock unit award originally granted on January 19, 2024. The shares were treated as a disposition at $5.60 per share, and Fabbio now directly holds 67,376 shares of Protara Therapeutics common stock after this administrative transaction.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Common Stock | 3,063 | $5.60 | $17K |
Footnotes (1)
- F1. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 19, 2024.
FAQ
What insider transaction did Protara Therapeutics (TARA) disclose for January 20, 2026?
Protara Therapeutics disclosed that its Chief Financial Officer, Patrick Fabbio, had 3,063 shares of common stock withheld on January 20, 2026 to satisfy income tax obligations related to a restricted stock unit vesting.
Was the Protara Therapeutics (TARA) CFO’s Form 4 transaction an open-market sale?
No. The Form 4 states the 3,063 shares were withheld by the issuer to cover income tax obligations from the vesting of a restricted stock unit award, rather than an open-market sale.
AI-generated analysis. How Rhea-AI works. Not financial advice.